Pharma owns the guitar. Mithrilome builds the amplifier.
Mithrilome is a discovery company using nature-derived chemistry to design add-on therapies for neurological and psychiatric disorders.
Mithrilome flew more than 100 microbial and cell-culture experiments to the International Space Station.
The brain is complicated. Why isn’t it being treated like it is?
Cancer care uses designed combinations of medicines. Neurological and psychiatric disorders are still mostly treated one drug at a time.
Cancer care
Designed combinations
Neurological and psychiatric disorders
One drug at a time
Add-on, not competitor.
Today’s neurological and psychiatric drugs are the guitar. Mithrilome is designing the add-on medicine that plugs in, so the signal can reach more patients, more strongly. In practice, an add-on is taken alongside a patient’s existing treatment, designed to help it work better rather than replace it.
-
Discover
We pair nature-derived chemistry with a computational discovery engine that decides what to test first.
-
Design
We design add-on therapies that complement current and emerging treatments, the way cancer care builds combinations.
-
Partner
We plan to develop programs with the companies that own those treatments. Add-on, by design.
Why now
19.7 million US adults had a major depressive episode in 2025.
$1.70 billion in 2025 worldwide sales for Spravato (esketamine, Johnson & Johnson), a newer treatment for treatment-resistant depression.
Sources: SAMHSA, 2025 National Survey on Drug Use and Health; Johnson & Johnson Form 10-K (FY2025).
